Type 2 helper T cell-selective immune response suppressors
First Claim
1. A method of inhibiting a type 2 helper T cell-selective immune response in a subject in need thereof, comprising administering to the subject a composition comprising a purine derivative represented by General Formula (I) whereinR2 is hydrogen or a C1-14 hydrocarbon in which —
- CH2—
not directly bound to the purine skeleton and CH2 in —
CH3 not directly bound to the purine skeleton may be substituted by carbonyl, sulfonyl, —
O—
or —
S—
;
═
CH2 may be substituted by ═
O or ═
S;
C—
H in CH2—
not directly bound to the purine skeleton, C—
H in —
CH3 not directly bound to the purine skeleton, C—
H in >
CH—
not directly bound to the purine skeleton, C—
H in ═
CH—
not directly bound to the purine skelton and C—
H in ═
CH2 may be substituted by N, C-halogen or C—
CN;
R6 is hydroxyl, amino or amino which is mono- or di-substituted by a C1-10 hydrocarbon group(s);
R8 is hydroxyl, mercapto, C1-18 acyloxy or C1-19 hydrocarbon group-substituting oxycarbonyloxy; and
R9 is a C1-14 hydrocarbon group in which —
CH2—
not directly bound to the purine skeleton and CH2 in —
CH3 not directly bound to the purine skeleton may be substituted by carbonyl, sulfonyl, —
O—
or —
S—
;
═
CH2 may be substituted by ═
O or ═
S;
C—
H in —
CH2—
not directly bound to the purine skeleton, C—
H in —
CH3 not directly bound to the purine skeleton, C—
H in >
CH—
not directly bound to the purine skeleton, C—
H in ═
CH—
not directly bound to the purine skeleton, C—
H in ═
CH2 and C—
H in ≡
CH may be substituted by N, C-halogen or C—
CN;
or its tautomer or a pharmaceutically acceptable salt of the purine derivative or the tautomer to inhibit a type 2-helper T cell-selective immune response.
3 Assignments
0 Petitions
Accused Products
Abstract
The present invention relates to a type 2 helper T cell-selective immune response inhibitor, an immune response regulator and an anti-allergic agent, individually comprising, as an active ingredient, a purine derivative represented by General Formula (I):
wherein
R2 is hydrogen or a hydrocarbon group in which —CH2— not directly bound to the purine skeleton may be substituted by CO, SO2, O or S, and C—H not directly bound to the purine skeleton may be substituted by N, C-halogen or C—CN;
R6 is hydroxyl, amino or amino which is mono- or di-substituted by a hydrocarbon group(s);
R8 is hydroxyl, mercapto, acyloxy or hydrocarbon group-substituting oxycarbonyloxy; and
R9 is a hydrocarbon group in which —CH2— not directly bound to the purine skeleton may be substituted by CO, SO2, O or S, and C—H not directly bound to the purine skeleton may be substituted by N, C-halogen or C—CN;
or its tautomer or a salt of the purine derivative or the tautomer.
287 Citations
6 Claims
-
1. A method of inhibiting a type 2 helper T cell-selective immune response in a subject in need thereof, comprising administering to the subject a composition comprising a purine derivative represented by General Formula (I)
wherein R2 is hydrogen or a C1-14 hydrocarbon in which — - CH2—
not directly bound to the purine skeleton and CH2 in —
CH3 not directly bound to the purine skeleton may be substituted by carbonyl, sulfonyl, —
O—
or —
S—
;
═
CH2 may be substituted by ═
O or ═
S;
C—
H in CH2—
not directly bound to the purine skeleton, C—
H in —
CH3 not directly bound to the purine skeleton, C—
H in >
CH—
not directly bound to the purine skeleton, C—
H in ═
CH—
not directly bound to the purine skelton and C—
H in ═
CH2 may be substituted by N, C-halogen or C—
CN;
R6 is hydroxyl, amino or amino which is mono- or di-substituted by a C1-10 hydrocarbon group(s);
R8 is hydroxyl, mercapto, C1-18 acyloxy or C1-19 hydrocarbon group-substituting oxycarbonyloxy; and
R9 is a C1-14 hydrocarbon group in which —
CH2—
not directly bound to the purine skeleton and CH2 in —
CH3 not directly bound to the purine skeleton may be substituted by carbonyl, sulfonyl, —
O—
or —
S—
;
═
CH2 may be substituted by ═
O or ═
S;
C—
H in —
CH2—
not directly bound to the purine skeleton, C—
H in —
CH3 not directly bound to the purine skeleton, C—
H in >
CH—
not directly bound to the purine skeleton, C—
H in ═
CH—
not directly bound to the purine skeleton, C—
H in ═
CH2 and C—
H in ≡
CH may be substituted by N, C-halogen or C—
CN;
or its tautomer or a pharmaceutically acceptable salt of the purine derivative or the tautomer to inhibit a type 2-helper T cell-selective immune response. - View Dependent Claims (3, 4)
- CH2—
-
2. A method of inhibiting a type 2 helper T cell-selective immune response in a subject in need thereof, comprising:
-
providing a composition comprising a purine derivative represented by General Formula (I)
whereinR2 is hydrogen or a C1-14 hydrocarbon in which —
CH2—
not directly bound to the purine skeleton and CH2 in —
CH3 not directly bound to the purine skeleton may be substituted by carbonyl, sulfonyl, —
O—
or —
S—
;
═
CH2 may be substituted by ═
O or ═
S;
C—
H in —
CH2—
not directly bound to the purine skeleton, C—
H in —
CH3 not directly bound to the purine skeleton, C—
H in >
CH—
not directly bound to the purine skeleton, C—
H in ═
CH—
not directly bound to the purine skelton and C—
H in ═
CH2 may be substituted by N, C-halogen or C—
CN;
R6 is hydroxyl, amino or amino which is mono- or di-substituted by a C1-10 hydrocarbon group(s);
R8 is hydroxyl, mercapto, C1-18 acyloxy or C1-19 hydrocarbon group-substituting oxycarbonyloxy; and
R9 is a C1-14 hydrocarbon group in which —
CH2—
not directly bound to the purine skeleton and CH2 in —
CH3 not directly bound to the purine skeleton may be substituted by carbonyl, sulfonyl, —
O—
or —
S—
;
═
CH2 may be substituted by ═
O or ═
S;
C—
H in —
CH2—
not directly bound to the purine skeleton, C—
H in —
CH3 not directly bound to the purine skeleton, C—
H in >
CH—
not directly bound to the purine skeleton, C—
H in ═
CH—
not directly bound to the purine skeleton, C—
H in ═
CH2 and C—
H in ≡
CH may be substituted by N, C-halogen or C—
CN;
or its tautomer or a pharmaceutically acceptable salt of the purine derivative or the tautomer; and
contacting the composition, directly or indirectly, to a type 2 helper T cell to inhibit a type 2 helper T cell-selective immune response.
-
-
5. A method of treating or preventing an allergic disease in a subject in need thereof, comprising administering to the subject a composition comprising a purine derivative represented by General Formula (I)
wherein R2 is hydrogen or a C1-14 hydrocarbon in which — - CH2—
not directly bound to the purine skeleton and CH2 in —
CH3 not directly bound to the purine skeleton may be substituted by carbonyl, sulfonyl, —
O—
or —
S—
;
═
CH2 may be substituted by ═
O or ═
S;
C—
H in —
CH2—
not directly bound to the purine skeleton, C—
H in —
CH3 not directly bound to the purine skeleton, C—
H in >
CH—
not directly bound to the purine skeleton, C—
H in ═
CH—
not directly bound to the purine skelton and C—
H in ═
CH2 may be substituted by N, C-halogen or C—
CN;
R6 is hydroxyl, amino or amino which is mono- or di-substituted by a C1-10 hydrocarbon group(s);
R8 is hydroxyl, mercapto, C1-18 acyloxy or C1-19 hydrocarbon group-substituting oxycarbonyloxy; and
R9 is a C1-14 hydrocarbon group in which —
CH2—
not directly bound to the purine skeleton and CH2 in —
CH3 not directly bound to the purine skeleton may be substituted by carbonyl, sulfonyl, —
O—
or —
S—
;
═
CH2 may be substituted by ═
O or ═
S;
C—
H in —
CH2—
not directly bound to the purine skeleton, C—
H in —
CH3 not directly bound to the purine skeleton, C—
H in >
CH—
not directly bound to the purine skeleton, C—
H in ═
CH—
not directly bound to the purine skeleton, C—
H in ═
CH2 and C—
H in ≡
CH may be substituted by N, C-halogen or C—
CN;
or its tautomer or a pharmaceutically acceptable salt of the purine derivative or the tautomer to treat or prevent an allergic disease.
- CH2—
-
6. A method of regulating an immune response in a subject in need thereof, comprising administering to the subject a composition comprising a purine derivative represented by General Formula (I)
wherein R2 is hydrogen or a C1-14 hydrocarbon in which — - CH2—
not directly bound to the purine skeleton and CH2 in —
CH3 not directly bound to the purine skeleton may be substituted by carbonyl, sulfonyl, —
O—
or —
S—
;
═
CH2 may be substituted by ═
O or ═
S;
C—
H in —
CH2—
not directly bound to the purine skeleton, C—
H in —
CH3 not directly bound to the purine skeleton, C—
H in >
CH—
not directly bound to the purine skeleton, C—
H in ═
CH—
not directly bound to the purine skelton and C—
H in ═
CH2 may be substituted by N, C-halogen or C—
CN;
R6 is hydroxyl, amino or amino which is mono- or di-substituted by a C1-10 hydrocarbon group(s);
R8 is hydroxyl, mercapto, C1-18 acyloxy or C1-19 hydrocarbon group-substituting oxycarbonyloxy; and
R9 is a C1-14 hydrocarbon group in which —
CH2—
not directly bound to the purine skeleton and CH2 in —
CH3 not directly bound to the purine skeleton may be substituted by carbonyl, sulfonyl, —
O—
or —
S—
;
═
CH2 may be substituted by ═
O or ═
S;
C—
H in —
CH2—
not directly bound to the purine skeleton, C—
H in —
CH3 not directly bound to the purine skeleton, C—
H in >
CH—
not directly bound to the purine skeleton, C—
H in ═
CH—
not directly bound to the purine skeleton, C—
H in ═
CH2 and C—
H in ≡
CH may be substituted by N, C-halogen or C—
CN;
or its tautomer or a pharmaceutically acceptable salt of the purine derivative or the tautomer to regulate an immune response.
- CH2—
Specification